The recent large prospective TailorX trial has confirmed that chemotherapy should be spared for HR positive, HER2 negative early stage breast cancer patients over 50 years old and a RS ≤ 25 or those 50 years or less and a RS ≤ 15 [14]. Here, ERBB2 is linked to breast cancer.